Platinum chromium everolimus-eluting stents for the treatment of (complex) coronary artery disease; from SYNERGY™ to the MEGATRON™

References

• Thornton MA, Gruentzig AR, Hollman J, et al. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation. 1984;69(4):721–727. doi: 10.1161/01.CIR.69.4.721
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315–1323. doi: 10.1056/NEJMoa035071
   PubMed Web of Science ®Google Scholar
• Hill RA, Dündar Y, Bakhai A, et al. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J. 2004;25(11):902–919. doi: 10.1016/j.ehj.2004.03.023
   PubMed Web of Science ®Google Scholar
• Tsimikas S. Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. J Am Coll Cardiol. 2006;47(10):2112–2115. doi: 10.1016/j.jacc.2006.03.019
   PubMed Web of Science ®Google Scholar
• Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356(10):998–1008. doi: 10.1056/NEJMoa067193
   PubMed Web of Science ®Google Scholar
• Kufner S, Joner M, Thannheimer A, et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: results from the ISAR-TEST 4 randomized trial. Circulation. 2019;139(3):325–333. doi: 10.1161/CIRCULATIONAHA.118.038065
   PubMed Web of Science ®Google Scholar
• Bangalore S, Toklu B, Patel N, et al. Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease: meta-analysis of randomized trials. Circulation. 2018;138(20):2216–2226. doi: 10.1161/CIRCULATIONAHA.118.034456
   PubMed Web of Science ®Google Scholar
• Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2014;100(2):153–159. doi: 10.1136/heartjnl-2013-304933
   PubMed Web of Science ®Google Scholar
• Wentzel JJ, Whelan D, Van Der Giessen WJ, et al. Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution. J Biomech. 2000;33(10):1287–1295. doi: 10.1016/S0021-9290(00)00066-X
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Ellis SG, Metzger DC, et al. Clinical outcomes before and after complete everolimus-eluting bioresorbable scaffold resorption: five-year follow-up from the ABSORB III trial. Circulation. 2019;140(23):1895–1903. doi: 10.1161/CIRCULATIONAHA.119.042584
   PubMed Web of Science ®Google Scholar
• Stone GW, Kimura T, Gao R, et al. Time-Varying Outcomes with the absorb bioresorbable vascular scaffold during 5-year follow-up: a Systematic Meta-analysis and individual patient data pooled study. JAMA Cardiol. 2019;4(12):1261–1269. doi: 10.1001/jamacardio.2019.4101
   PubMed Web of Science ®Google Scholar
• Haude M, Wlodarczak A, van der Schaaf RJ, et al. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study. eClinicalmedicine. 2023;59:101940. doi: 10.1016/j.eclinm.2023.101940
   PubMedGoogle Scholar
• Mohamed MO, Polad J, Hildick-Smith D, et al. Impact of coronary lesion complexity in percutaneous coronary intervention: one-year outcomes from the large, multicentre e-ultimaster registry. EuroIntervention. 2021;16(7):603–612. doi: 10.4244/EIJ-D-20-00361
   Web of Science ®Google Scholar
• Généreux P, Giustino G, Redfors B, et al. Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. Int J Cardiol. 2018;268:61–67. doi: 10.1016/j.ijcard.2018.03.103
   PubMed Web of Science ®Google Scholar
• Gargiulo G, Patialiakas A, Piccolo R, et al. Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. Int J Cardiol. 2019;277:60–65. doi: 10.1016/j.ijcard.2018.09.120
   PubMed Web of Science ®Google Scholar
• Doost A, Rankin J, Sapontis J, et al. Contemporary evidence-based diagnosis and management of severe coronary artery calcification. Heart Lung Circ. 2022;31(6):766–778. doi: 10.1016/j.hlc.2022.01.011
   PubMed Web of Science ®Google Scholar
• Holm NR, Andreasen LN, Neghabat O, et al. OCT or angiography guidance for PCI in complex bifurcation lesions. N Engl J Med. 2023;389(16):1477–1487. doi: 10.1056/NEJMoa2307770
   PubMed Web of Science ®Google Scholar
• Lee JM, Choi KH, Bin SY, et al. Intravascular imaging–guided or angiography-guided complex PCI. N Engl J Med. 2023;388:1668–1679.
   PubMed Web of Science ®Google Scholar
• Parker W, Iqbal J. Comparison of contemporary drug-eluting coronary stents – is any stent better than the others? Heart Int. 2020;14(1):34–42. doi: 10.17925/HI.2020.14.1.34
   PubMed Web of Science ®Google Scholar
• Bennett J, Dubois C. A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease. Biol Targets Ther. 2013;7:149–159. doi: 10.2147/BTT.S34939
   PubMedGoogle Scholar
• Dabry T, Laine M, Bonello L, et al. OCT analysis of early endothelialization of the synergy stent in young non-ST segment elevation acute coronary syndrome. The OCT EROS study. Arch Cardiovasc Dis Suppl. 2019;11(1):e283–e284. doi: 10.1016/j.acvdsp.2019.01.003
   Google Scholar
• Wilson GJ, Marks A, Berg KJ, et al. The SYNERGY biodegradable polymer everolimus eluting coronary stent: porcine vascular compatibility and polymer safety study. Catheter Cardiovasc Interv. 2015;86(6):E247–E257. doi: 10.1002/ccd.25993
   PubMed Web of Science ®Google Scholar
• Kirtane AJ, Stoler R, Feldman R, et al. Primary results of the EVOLVE short DAPT study: evaluation of 3-month dual antiplatelet therapy in high bleeding risk patients treated with a bioabsorbable polymer-coated everolimus-eluting stent. Circ Cardiovasc Interv. 2021;14(3):E010144. doi: 10.1161/CIRCINTERVENTIONS.120.010144
   PubMed Web of Science ®Google Scholar
• Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64(1):36–42. doi: 10.1097/00007890-199707150-00008
   PubMed Web of Science ®Google Scholar
• Samant S, Wu W, Zhao S, et al. Computational and experimental mechanical performance of a new everolimus-eluting stent purpose-built for left main interventions. Sci Rep. 2021;11(1):1–14. doi: 10.1038/s41598-021-87908-2
   PubMed Web of Science ®Google Scholar
• Ng J, Foin N, Ang HY, et al. Over-expansion capacity and stent design model: an update with contemporary DES platforms. Int J Cardiol. 2016;221:171–179. doi: 10.1016/j.ijcard.2016.06.097
   PubMed Web of Science ®Google Scholar
• Mailey JA, Ahmed M, Hogg M, et al. Initial experiences of percutaneous coronary intervention using a new-generation everolimus-eluting stent platform. J Invasive Cardiol. 2021;33(10):E784–E790.
   PubMed Web of Science ®Google Scholar
• Giannoglou GD, Antoniadis AP, Chatzizisis YS, et al. Prevalence of narrowing ≥50% of the left main coronary artery among 17,300 patients having coronary angiography. Am J Cardiol. 2006;98(9):1202–1205. doi: 10.1016/j.amjcard.2006.05.052
   PubMed Web of Science ®Google Scholar
• Neumann F-J, Sousa-Uva M, Ahlsson A, et al. ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2018;14(14):1435–1534. doi: 10.4244/EIJY19M01_01
   Web of Science ®Google Scholar
• Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation. 2022;145:E4–E17.
   PubMed Web of Science ®Google Scholar
• Kinnaird T, Johnson T, Anderson R, et al. Intravascular imaging and 12-month mortality after unprotected left main stem PCI: an analysis from the british cardiovascular intervention society database. JACC: Cardiovasc Interv. 2020;13(3):346–357. doi: 10.1016/j.jcin.2019.10.007
   PubMed Web of Science ®Google Scholar
• Kervinen K, Niemelä M, Romppanen H, et al. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the nordic stent technique study 36-month follow-up results. JACC: Cardiovasc Interv. 2013;6(11):1160–1165. doi: 10.1016/j.jcin.2013.06.009
   PubMed Web of Science ®Google Scholar
• Walsh SJ, Hanratty CG, Watkins S, et al. Culotte stenting for coronary bifurcation lesions with 2nd and 3rd generation everolimus-eluting stents: the CELTIC bifurcation study. EuroIntervention. 2018;14(3):e318–e324. doi: 10.4244/EIJ-D-18-00346
   PubMed Web of Science ®Google Scholar
• Behan MW, Holm NR, De Belder AJ, et al. Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the nordic bifurcation study and the British bifurcation coronary study. Eur Heart J. 2016;37(24):1923–1928. doi: 10.1093/eurheartj/ehw170
   PubMed Web of Science ®Google Scholar
• Kinnaird T, Gallagher S, Anderson R, et al. Are higher operator volumes for unprotected left main stem percutaneous coronary intervention associated with improved patient outcomes: a survival analysis of 6724 procedures from the british cardiovascular intervention society national database. Circ: Cardiovascular Interventions. 2020;13(6):1–10. doi: 10.1161/CIRCINTERVENTIONS.119.008782
   Web of Science ®Google Scholar
• Punamiya K, Jha T, Punamiya V, et al. IVUS determination of normal left main stem artery size and plaque burden, and correlation with body surface area in an Indian population. AsiaIntervention. 2022;8(2):116–122. doi: 10.4244/AIJ-D-22-00041
   PubMedGoogle Scholar
• Dodge JT, Brown BG, Bolson EL, et al. Lumen diameter of normal human coronary arteries. Influence of age, sex, anatomic variation, and left ventricular hypertrophy or dilation. Circulation. 1992;86(1):232–246. doi: 10.1161/01.CIR.86.1.232
   PubMed Web of Science ®Google Scholar
• Meredith IT, Verheye S, Dubois C, et al. Final five-year clinical outcomes in the EVOLVE trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention. 2018;13(17):2047–2050. doi: 10.4244/EIJ-D-17-00529
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Windecker S, Jobe RL, et al. Clinical outcomes following implantation of thin-strut, bioabsorbable polymer-coated, everolimus-eluting SYNERGY stents: final 5-year results of the EVOLVE II randomized trial. Circ Cardiovasc Interv. 2019;12(9):1–9. doi: 10.1161/CIRCINTERVENTIONS.119.008152
   Web of Science ®Google Scholar
• Maeng M, Christiansen EH, Raungaard B, et al. Everolimus-eluting versus biolimus-eluting stents with biodegradable polymers in unselected patients undergoing percutaneous coronary intervention: a randomized noninferiority trial with 1-year follow-up (SORT OUT VIII trial). JACC: Cardiovasc Interv. 2019;12(7):624–633. doi: 10.1016/j.jcin.2018.12.036
   PubMed Web of Science ®Google Scholar
• Ploumen EH, Pinxterhuis TH, Buiten RA, et al. Final 5-year report of the randomized BIO-RESORT trial comparing 3 contemporary drug-eluting stents in all-comers. J Am Heart Assoc. 2022;11(22):11. doi: 10.1161/JAHA.122.026041
   Web of Science ®Google Scholar
• Walsh SJ, Hanratty CG, McEntegart M, et al. Intravascular healing is not affected by approaches in contemporary CTO PCI: the CONSISTENT CTO study. JACC: Cardiovasc Interv. 2020;13(12):1448–1457. doi: 10.1016/j.jcin.2020.03.032
   PubMed Web of Science ®Google Scholar
• van Geuns RJ, Chun-Chin C, McEntegart MB, et al. Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial. EuroIntervention. 2022;17(18):1467–1476. doi: 10.4244/EIJ-D-21-00514
   PubMed Web of Science ®Google Scholar
• Varenne O, Cuisset T, Chaïb A, et al. The SYNERGY II everolimus elutiNg stent in patients older than 75 years undergoing coronary revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study. EuroIntervention. 2017;12(13):1614–1622. doi: 10.4244/EIJY15M12_02
   PubMed Web of Science ®Google Scholar
• Pivato CA, Reimers B, Testa L, et al. One-month dual antiplatelet therapy after bioresorbable polymer everolimus-eluting stents in high bleeding risk patients. J Am Heart Assoc. 2022;11(6):11. doi: 10.1161/JAHA.121.023454
   Web of Science ®Google Scholar
• De Silva K, Kam Wa ME L, Wells T, et al. The everolimus eluting synergy megatron TM drug-eluting stent platform: early outcomes from the European synergy megatron TM Implanters’ registry. Cathet Cardio Intervent. 2023;102(7):1222–1228. doi: 10.1002/ccd.30902
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Kini AS, Karmpaliotis D, et al. Safety and effectiveness of everolimus-eluting stents in chronic total coronary occlusion revascularization: results from the EXPERT CTO multicenter trial (evaluation of the XIENCE coronary stent, performance, and technique in chronic total occlusions). JACC: Cardiovasc Interv. 2015;8(6):761–769. doi: 10.1016/j.jcin.2014.12.238
   PubMed Web of Science ®Google Scholar
• Andreasen LN, Balleby IR, Barkholt T, et al. Early healing after treatment of coronary lesions by thin strut everolimus, or thicker strut biolimus eluting bioabsorbable polymer stents: the SORT-OUT VIII OCT study. Catheter Cardiovasc Interv. 2023;101(4):787–797. doi: 10.1002/ccd.30579
   PubMed Web of Science ®Google Scholar
• Vesga B, Hernandez H, Moncada M, et al. Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study. Coron Artery Dis. 2017;28(2):126–134. doi: 10.1097/MCA.0000000000000453
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Amjadi N, Caputo C, et al. One-year Outcomes in “real-world” patients treated with a thin-strut, platinum-chromium, everolimus-eluting stent (from the PROMUS element plus US post-approval study [PE-Plus PAS]). Am J Cardiol. 2016;117(4):539–545. doi: 10.1016/j.amjcard.2015.11.043
   PubMed Web of Science ®Google Scholar
• Thomas MR, Birkemeyer R, Schwimmbeck P, et al. One-year outcomes in 1,010 unselected patients treated with the PROMUS element everolimus-eluting stent: the multicentre PROMUS element European post-approval surveillance study. EuroIntervention. 2015;10(11):1267–1271. doi: 10.4244/EIJY15M01_07
   PubMed Web of Science ®Google Scholar
• Chatzizisis YS, Makadia J, Zhao S, et al. First-in-human computational preprocedural planning of left main interventions using a new everolimus-eluting stent. JACC: Case Rep. 2022;4(6):325–335. doi: 10.1016/j.jaccas.2022.02.001
   PubMedGoogle Scholar
• Mohammad MA, Persson J, Buccheri S, et al. Trends in clinical practice and outcomes after percutaneous coronary intervention of unprotected left main coronary artery. J Am Heart Assoc. 2022;11(7):11. doi: 10.1161/JAHA.121.024040
   Web of Science ®Google Scholar
• Hildick-Smith D, Egred M, Banning A, et al. The European bifurcation club left main coronary stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN). Eur Heart J. 2021;42(37):3829–3839. doi: 10.1093/eurheartj/ehab283
   PubMed Web of Science ®Google Scholar
• Madhavan MV, Kirtane AJ, Redfors B, et al. Stent-related adverse events >1 year after percutaneous coronary intervention. J Am Coll Cardiol. 2020;75(6):590–604. doi: 10.1016/j.jacc.2019.11.058
   PubMed Web of Science ®Google Scholar
• Saito S, Bennett J, Nef HM, et al. First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with de novo coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international. BIODAPT eClinicalMedicine. 2023;65:102304. doi: 10.1016/j.eclinm.2023.102304
   PubMedGoogle Scholar
• Cherian AM, Nair SV, Maniyal V, et al. Surface engineering at the nanoscale: a way forward to improve coronary stent efficacy. APL Bioeng. 2021;5(2):1–28. doi: 10.1063/5.0037298
   Web of Science ®Google Scholar
• Vishnu J, Manivasagam G. Perspectives on smart stents with sensors: from conventional permanent to novel bioabsorbable smart stent technologies. Med Devices Sens. 2020;3(6):1–10. doi: 10.1002/mds3.10116
   Google Scholar